A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
This is a phase III , randomized, double-blinded, multicenter clinical study to compare
efficacy and safety of AK105 (Anti-PD1 antibody) combined with Carboplatin and Pemetrexed vs
Placebo combined with Carboplatin and Pemetrexed as first-line therapy in patients with EGFR
and ALK wild type metastatic nonsquamous non-small cell lung cancer.